Immunolabelling of Acetylated Histones 3 and 4 and Histone Deacetylases 1, 2 and 6 in Canine Soft Tissue Sarcomas. (May 2022)

• Record Type: Journal Article
• Authors: Sena, Bruna V.; Horta, Rodrigo S.; Senhorello, Igor L.S.; Matiz, Oscar R.S.; Canavari, Isabela C.; Souza, Larissa M.; Ferreira, Marília G.P.A.; Sueiro, Felipe A.R.; Costa, Mirela T.; de Nardi, Andrigo B.
• Is Part Of: Journal of comparative pathology. Volume 193(2022)
• Page Start: 51
• Page End: 58
• Publication Date: 2022-05
• Subjects: canine -- epigenetic -- histones -- mesenchymal neoplasia; Veterinary pathology -- Periodicals; Veterinary therapeutics -- Periodicals; Pathology, Comparative -- Periodicals; Therapeutics -- Periodicals; Pathology, Veterinary -- Periodicals; 636.089607
• DOI: 10.1016/j.jcpa.2022.03.001
• Languages: English
• ISSNs: 0021-9975

Abstract

Summary: The objective of this study was to investigate the immunolabelling of acetylated histones and histone desacetylase (HDAC) enzymes in canine soft tissue sarcomas (STSs) and to correlate them with histological and clinical features in order to identify possible prognostic and therapeutic targets in these neoplasms. Fifteen canine STS samples were evaluated and were submitted to immunohistochemistry for acetylated histones 3 (H3) and 4 (H4) and deacetylating enzymes (HDAC1, HDAC2 and HDAC6). Intense immunolabelling of H4 was seen in comparison with H3. A strong positive correlation was observed between the H3 intensity score and the number of mitotic figures ( P = 0.004, r = 0.7). Intense immunolabelling of HDAC1 was found in comparison to the expression of HDAC2 and HDAC6 in the evaluated STSs. This finding suggests that HDAC1 may be a potential target for HDAC inhibitors in STSs in dogs.